Drug · CHEMBL4
OFLOXACIN
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. OFLOXACIN. Drugs and targets, record CHEMBL4. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL4
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Open Targets' highest stage
- Approval, for 7 of its 19 diseases, from ATC, DailyMed and TTD
- Open Targets
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases19
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 19Source Open Targets
See all 19 diseasesTrials29
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT02567825 | Efficacy of Tympanostomy Tubes for Children With Recurrent Acute Otitis Media | 250 | 2021-12-10 | ofloxacin | Its name | ClinicalTrials.gov | |
| NCT00002850 | Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy | Phase 3 | 212 | 2015-02-13 | ofloxacin | Its name | ClinicalTrials.gov |
| NCT02528123 | VisuMax Femtosecond Laser Small Incision Lenticule Extraction for the Correction of High Myopia | 114 | 2024-04-23 | ofloxacin | Its name | ClinicalTrials.gov | |
| NCT02373137 | Descemet Endothelial Thickness Comparison Trial | Phase 4 | 38 | 2019-07-02 | ofloxacin | Its name | ClinicalTrials.gov |
| NCT00042289 | Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy | 1,578 | 2022-07-22 | ofloxacin | Its name | ClinicalTrials.gov | |
| NCT01799356 | Moxifloxacin Versus Ofloxacin Plus Metronidazole in Uncomplicated Pelvic Inflammatory Disease: Multicenter Randomized Controlled Trials | Phase 4 | 1,303 | ofloxacin | Its name | ClinicalTrials.gov | |
| NCT00578474 | A Phase III Study of an Otic Formulation in Acute Otitis Media With Tympanostomy Tubes | Phase 3 | 911 | ofloxacin | Its name | ClinicalTrials.gov | |
| NCT00683865 | Uncomplicated Pelvic Inflammatory Disease. Treatment With Moxifloxacin. | Phase 3 | 749 | ofloxacin | Its name | ClinicalTrials.gov | |
| NCT00563394 | MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers | Phase 3 | 584 | ofloxacin | Its name | ClinicalTrials.gov | |
| NCT00563433 | MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers | Phase 3 | 342 | ofloxacin | Its name | ClinicalTrials.gov |
1 to 10 of 29
See all 29 trialsComparisons in its trials4
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Surgical Management vs Non-Surgical Management: deaths from any cause | 0 of 129 | 0 of 121 | 250 | NCT02567825 | Trial comparisons |
| Surgical Management vs Non-Surgical Management: serious adverse events | 3 of 129 | 7 of 121 | 250 | NCT02567825 | Trial comparisons |
| UT-DSAEK vs DMEK: deaths from any cause | 0 of 25 | 0 of 25 | 50 | NCT02373137 | Trial comparisons |
| UT-DSAEK vs DMEK: serious adverse events | 0 of 25 | 0 of 25 | 50 | NCT02373137 | Trial comparisons |
Papers from its trials57
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL4
GET https://conductscience.org/api/drugs/v1/CHEMBL4/trials?page=2